Citadel Advisors
CLYM

Citadel Advisors’s Climb Bio CLYM Stock Holding History

Citadel Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.37M Buy
345,663
+106,620
+45% +$615K ﹤0.01% 5739
2025
Q4 		$956K Buy
+239,043
New +$574K ﹤0.01% 7495
2025
Q3 		– Sell
-138,392
Closed -$172K – 14448
2025
Q2 		$172K Buy
138,392
+55,638
+67% +$69.2K ﹤0.01% 10829
2025
Q1 		$101K Buy
82,754
+16,282
+24% +$26.4K ﹤0.01% 11448
2024
Q4 		$120K Buy
+66,472
New +$241K ﹤0.01% 11197
2022
Q4 		– Sell
-11,587
Closed -$37K – 15566
2022
Q3 		$37K Sell
11,587
-3,624
-24% -$11.6K ﹤0.01% 11800
2022
Q2 		$46K Buy
+15,211
New +$72K ﹤0.01% 11994

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citadel Advisors's CLYM Position: Q1 2026 in Review

Citadel Advisors increased its Climb Bio (CLYM) stake by 45% in Q1 2026, buying an estimated $615K and bringing the position to 345,663 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #5739.

Citadel Advisors first reported a position in CLYM in Q2 2022 and has held it in 7 quarters since. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Citadel Advisors held 345,663 shares of Climb Bio worth $2.37M as of Q1 2026.
  • Citadel Advisors bought 106,620 Climb Bio shares in Q1 2026, an estimated $615K.
  • Climb Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5739 holding.
  • Citadel Advisors first reported a position in Climb Bio in Q2 2022 and has held it in 7 quarters since.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.